NICE does not recommend Otezla (apremilast) for treatment of psoriatic arthritis- Celgene
The National Institute for Care and Health Excellence (NICE) in draft guidance does not recommend Otezla (apremilast) from Celgene, alone or in combination with disease-modifying antirheumatic drug (DMARD) therapy as a treatment for psoriatic arthritis as the incremental cost effectiveness ratios for Otezla were substantially over �30 000 per QALY gained and thus not cost effective.
Comment: Earlier in the month NICE rejected Otezla for treatment of patients with moderate to severe psoriasis on the ground of lack of cost effectiveness, however the drug was accepted by regulators in Scotland.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.